Argenx announced encouraging preliminary data for its antibody drug Vyvgart in two additional autoimmune diseases beyond its approved indications. The company is testing Vyvgart in multiple disease settings, potentially expanding its market footprint significantly. This progress supports Argenx’s strategic growth in autoimmune therapeutics.